- Home
- SAVA vs PBI Comparison
SAVA vs PBI Comparison
Compare SAVA & PBI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SAVA
- PBI
- Stock Information
- Founded
- SAVA 1998
- PBI 1920
- Country
- SAVA United States
- PBI United States
- Employees
- SAVA N/A
- PBI N/A
- Industry
- SAVA Biotechnology: Pharmaceutical Preparations
- PBI Office Equipment/Supplies/Services
- Sector
- SAVA Health Care
- PBI Miscellaneous
- Exchange
- SAVA Nasdaq
- PBI Nasdaq
- Market Cap
- SAVA 1.3B
- PBI 1.3B
- IPO Year
- SAVA N/A
- PBI N/A
- Fundamental
- Price
- SAVA $27.08
- PBI $6.92
- Analyst Decision
- SAVA Buy
- PBI
- Analyst Count
- SAVA 3
- PBI 0
- Target Price
- SAVA $107.00
- PBI N/A
- AVG Volume (30 Days)
- SAVA 1.9M
- PBI 1.5M
- Earning Date
- SAVA 11-05-2024
- PBI 10-31-2024
- Dividend Yield
- SAVA N/A
- PBI 2.90%
- EPS Growth
- SAVA N/A
- PBI N/A
- EPS
- SAVA N/A
- PBI N/A
- Revenue
- SAVA N/A
- PBI $3,279,008,000.00
- Revenue This Year
- SAVA N/A
- PBI N/A
- Revenue Next Year
- SAVA N/A
- PBI N/A
- P/E Ratio
- SAVA N/A
- PBI N/A
- Revenue Growth
- SAVA N/A
- PBI N/A
- 52 Week Low
- SAVA $8.79
- PBI $3.03
- 52 Week High
- SAVA $42.20
- PBI $7.70
- Technical
- Relative Strength Index (RSI)
- SAVA 46.80
- PBI 50.76
- Support Level
- SAVA $26.10
- PBI $6.74
- Resistance Level
- SAVA $31.65
- PBI $7.27
- Average True Range (ATR)
- SAVA 2.55
- PBI 0.22
- MACD
- SAVA -0.50
- PBI -0.02
- Stochastic Oscillator
- SAVA 15.08
- PBI 42.06
About SAVA Cassava Sciences Inc.
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx, and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia.
About PBI Pitney Bowes Inc.
Pitney Bowes is a Global technology company that offers e-commerce solutions to its clients. The company provides various products and services such as domestic delivery, return and fulfillment, cross-border shipping solutions, sorting services for large volumes of postal mails, technological solutions to enable digital mailing, shipping, and other services. The company operates through three business segments: Global e-commerce, presort services, and SendTech Solutions. The company generates majority of its revenue from United States.